M. Michelle Berrey, M.D., M.P.H. has been appointed president and chief executive officer of Chimerix, Inc. Dr. Berrey will continue to serve as chief medical officer. Dr. Berrey succeeds Kenneth I. Moch, who has resigned to pursue other interests.
Prior to joining the company, Dr. Berrey served as chief medical officer at Pharmasset, Inc. since 2007, a company focused on the development of nucleotide analogs for the treatment of hepatitis C, until its acquisition by Gilead Sciences, Inc. in January 2012.
"We are grateful for Ken's contributions to Chimerix and his leadership during the company's transition to a publicly traded company. We are now entering a critical stage of the clinical development of brincidofovir. Our goal is to complete the requirements for regulatory approval of brincidofovir as rapidly as possible and we believe Dr. Berrey has the qualifications and expertise in abundance to accomplish that objective," said Ernest Mario, Ph.D., chairman of the board of directors. "I believe Dr. Berrey has demonstrated the leadership skills and vision to guide Chimerix through this critical phase in the company's evolution.”